Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Author:
Funder
European Research Council
Medical Research Council
Wellcome Trust
Cancer Research UK
Publisher
Elsevier BV
Reference174 articles.
1. The Frequency of Ras Mutations in Cancer;Prior;Cancer Res.,2020
2. Targeting RAS signalling pathways in cancer therapy;Downward;Nat. Rev. Cancer,2003
3. The current state of the art and future trends in RAS-targeted cancer therapies;Punekar;Nat. Rev. Clin. Oncol.,2022
4. RAS oncogenes: weaving a tumorigenic web;Pylayeva-Gupta;Nat. Rev. Cancer,2011
5. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer;Adjei;J. Clin. Oncol.,2003
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS‐mutant Cancers;Advanced Science;2024-09-10
2. KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening;Molecular Oncology;2024-09-10
3. Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer;Frontiers in Oncology;2024-09-05
4. 19Fluorine‐MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer;Journal of Magnetic Resonance Imaging;2024-08-27
5. Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors;Proceedings of the National Academy of Sciences;2024-08-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3